Essential blepharospasm: Practice-oriented therapy with botulinum toxin employing reduced treatment intervals; [Essenzieller Blepharospasmus: Praxisnahe Therapie mit Botulinumtoxin unter Verwendung verkürzter Behandlungsintervalle]

被引:0
作者
Wabbels B. [1 ]
Roggenkämper P. [1 ]
机构
[1] Universitäts-Augenklinik Bonn, 53127 Bonn
来源
Der Ophthalmologe | 2012年 / 109卷 / 1期
关键词
Botulinum toxin; Duration of effect; Essential blepharospasm; Injection interval; Xeomin;
D O I
10.1007/s00347-011-2457-z
中图分类号
学科分类号
摘要
Background: Botulinum neurotoxin injections are a primary symptomatic treatment for blepharospasm. Injections are generally repeated every 3 months. For patients with short-term treatment effects there have therefore been long intervals without sufficient treatment effects, as reinjections have previously been avoided due to concerns of increased side effects or production of antibodies against complexing proteins. Methods: As Xeomin® is a pure A botulinum toxin type complexing proteins are not present. We have hence decided to treat appropriate patients with injection intervals of 10 or less weeks if these patients have been suffering from psychological stress. Patients: In 11 of these patients the typical patient characteristics and course of therapy were analyzed. There were no relevant adverse events. In all patients, time periods without treatment effect were shorter or no longer present. In 6 patients injection intervals could be prolonged after several injections due to the good effect. Conclusion: An optimized therapy of essential blepharospasm should not only take dose, dose distribution and injections site into account but also injection intervals. Reinjections could be performed if necessary after at least 6 weeks. © 2011 Springer-Verlag.
引用
收藏
页码:45 / 53
页数:8
相关论文
共 33 条
  • [1] Atassi M.Z., Basic immunological aspects of botulinum toxin therapy, Mov Disord, 19, SUPPL. 8, pp. 68-84, (2004)
  • [2] Bentivoglio A.R., Fasano A., Ialongo T., Et al., Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs, Neurotox Res, 15, pp. 224-231, (2009)
  • [3] Borodic G., Immunologic resistance after repeated botulinum toxin type a injections for facial rhytides, Ophthal Plast Reconstr Surg, 22, pp. 239-240, (2006)
  • [4] Brin M.F., Comella C.L., Jankovic J., Et al., Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay, Mov Disord, 23, pp. 1353-1360, (2008)
  • [5] Ceballos-Baumann A.O., Dystonien, Bewegungsstörungen in der Neurologie, (1996)
  • [6] Chinnapongse R., Lew M.F., Pagan F., Et al., A 7-year open-label safety and immunogenicity study of Myobloc in patients with cerviacal dystonia, Neurology, 74, pp. 86-87, (2010)
  • [7] Dressler D., Complete secondary botulinum toxin therapy failure in blepharospasm, J Neurol, 247, pp. 809-810, (2000)
  • [8] Dressler D., Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy, Eur Neurol, 48, pp. 26-29, (2002)
  • [9] Dressler D., New formulation of BOTOX. Complete antibody-induced therapy failure in hemifacial spasm, J Neurol, 251, (2004)
  • [10] Dressler D., Bigalke H., Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure, J Neurol, 252, pp. 904-907, (2005)